Ausgewählte Publikationen
Theranostics. 2019 Feb 20;9(5):1490-1509. doi: 10.7150/thno.29546.
Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers.
Goody D, Gupta SK, Engelmann D, Spitschak A, Marquardt S, Mikkat S, Meier C, Hauser C, Gundlach JP, Egberts JH, Martin H, Schumacher T, Trauzold A, Wolkenhauer O, Logotheti S, Pützer BM.
Semin Cancer Biol. 2018 Jun 29. pii: S1044-579X(18)30018-X. doi: 10.1016/j.
Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
Marquardt S, Solanki M, Spitschak A, Vera J, Pützer BM.
Theranostics 2018; 8(4):1106-1120.
MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance.
Lai X, Gupta SK, Schmitz U, Marquardt S, Knoll S, Spitschak A, Wolkenhauer O, Pützer BM, Vera J.
Mol Cancer. 2017 Jan 26;16(1):24.
MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A, Meier C, Kowtharapu B, Engelmann D, Pützer BM
Viral Vector, Use There of For Therapy Of Liver Cell Carcinomas And Pharmaceutical Composition Comprising The Vector (PVA1142 DE 10 2005055 128)
European Patent PVA1158EP 1985708/2015 – Selective targeting of virusesto neural precursor cells